SHY-1306

N/A

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameSHY-1306
Drug Alias NameEGFR L858R/T790M mutant inhibitors (Shanghai Haiyan Pharmaceutical Technology)SHY-1306
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Haiyan Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Haiyan Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A